natural glp 1 receptor agonist America's Poison Centers Potential Use of GLP-1 and

doi: 10.1016/S0140-6736(12)60479-6 [DOI] [PubMed] [Google Scholar] 44

CPAA (2022) 14:1926

BY REGION The GLP-1 agonists market covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Results from 8 randomized controlled trials (6 361 participants) indicated that these effects might last up to 3.5 years, although long-term safety data remain limited

With favorable results, it might become a first-in-class fixed-dose injectable therapy for both obesity and T2DM

Conclusion GLP-1RA and SGLT2-I are efficacious second-line treatments for T2DM with limited risk of hypoglycemia and positive or neutral effects on CV risk, weight, and BP